Hikma Pharmaceuticals Plc Product Launch (4075T)
December 13 2012 - 2:00AM
UK Regulatory
TIDMHIK
RNS Number : 4075T
Hikma Pharmaceuticals Plc
13 December 2012
PRESS RELEASE
Hikma launches argatroban injection
London, 13 December 2012 - Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK) ("Hikma"), the fast growing multinational
pharmaceutical group, today announces the US launch of argatroban
injection, following the approval of its New Drug Application (NDA)
by the US Food and Drug Administration (FDA) earlier this year.
Hikma's argatroban is indicated for the prophylaxis or treatment
of thrombosis in adult patients with heparin-induced
thrombocytopenia (HIT) and as an anticoagulant in adult patients
with or at risk of HIT undergoing percutaneous coronary
intervention (PCI).
Said Darwazah, CEO of Hikma, said, "Hikma is pleased to be
bringing argatroban injection to market. Argatroban will expand our
injectables product line and help to differentiate our product
portfolio in the US."
According to IMS Health, sales of argatroban injection were
approximately $105 million for the 12 months ending October 2012.
Hikma is marketing argatroban injection in 100mg/ml vials. Hikma's
argatroban was developed through Hikma's partnership with the
specialty pharmaceutical company, Exela Pharma Sciences, LLC.
----- ENDS -----
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations
+44 (0)20 7399 2760/
FTI Consulting
Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole
+44 (0)20 7831 3113
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational
pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non-branded generic and
in-licensed products. Hikma's operations are conducted through
three businesses: "Branded", "Injectables" and "Generics" based
principally in the Middle East and North Africa ("MENA") region,
where it is a market leader, the United States and Europe. In 2011,
Hikma achieved revenues of $918 million and profit attributable to
shareholders of $80.1 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
PRLLLFERFLLFLIF
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024